文献速递免疫规划

三抗原乙肝疫苗两个生产批次在健康亚洲成人中的免疫原性与安全性:3期随机临床试验

Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: A phase 3 randomized clinical trial.
PubMed 文献 · Vaccine · 2021-06-08

本研究在越南单中心开展3期单盲随机试验,比较三抗原乙肝疫苗(3A-HBV)两个生产批次(A和B)与单抗原疫苗Engerix-B的免疫原性和安全性。主要终点为第210天血清保护率(SPR,抗-HBs≥10 mIU/mL)的批次间等效性。结果显示两批次等效,但批次B血清保护更快、抗-HBs滴度更高,且安全性良好。

要点

  • 3A-HBV批次A与批次B在第210天血清保护率等效(97.3% vs 100.0%)。
  • 批次B第180天SPR高于Engerix-B(98.3% vs 81.2%),第210天非劣效。
  • 批次B接种2剂后SPR(98.3%)与Engerix-B接种3剂后相同(98.3%)。

核心结论

  • 两个3A-HBV生产批次免疫原性等效,批次B血清保护出现更快、抗-HBs滴度更高,安全性良好。

研究设计与样本

  • 3期单盲随机临床试验,在越南一个中心开展,比较3A-HBV批次A、批次B与单抗原乙肝疫苗Engerix-B。
  • 主要目标为第210天两批次血清保护率(抗-HBs≥10 mIU/mL)等效性。

主要发现

  • 第210天SPR:批次A 97.3%(95%CI 92.4%-99.4%),批次B 100.0%(95%CI 97.0%-100.0%)。
  • 与Engerix-B相比,批次B第180天SPR更高(98.3% vs 81.2%;差值17.1%[9.7%,24.6%]),第210天非劣效(100% vs 98.3%;差值1.7%[-0.6%,4.1%])。
  • 批次B接种2剂后SPR(98.3%)与Engerix-B接种3剂后(98.3%)相同。
  • 不良事件发生率:批次A 68.7%、批次B 54.2%、Engerix-B 35.3%;疫苗相关不良事件包括短暂注射部位疼痛(38.9%)、肌痛(9.3%)、疲劳(7.5%)。
  • 严重不良事件8例:批次A 3/134(2.2%)、批次B 1/134(0.8%)、Engerix-B 4/133(2.3%);1例晕厥(批次B)可能与疫苗相关。

临床怎么用

  • 3A-HBV批次B可作为乙肝疫苗接种的有效选择,具有有利的安全性特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sci-B-Vac®, a 3-antigen hepatitis B vaccine (3A-HBV), contains all three recombinant hepatitis B virus (HBV) envelope proteins (S, pre-S1, and pre-S2). In 2005, 3A-HBV manufacturing transferred facilities (A to B), where it continues to be manufactured. METHODS: This phase 3, single-blind, randomized study, conducted at one site in Vietnam, compared efficacy and safety among two 3A-HBV lots, lot A and lot B, and a single-antigen hepatitis B vaccine (1A-HBV), Engerix-B®. Primary objective was to demonstrate equivalence at day 210 of two 3A-HBV lots in seroprotection rate (SPR; defined as percentage of participants achieving hepatitis B surface antigen antibody [anti-HBs] titers ≥ 10 mIU/mL). Secondary objectives were assessing immunogenicity at days 180, 210, and 360, and safety of 3A-HBV. RESULTS: 3A-HBV SPR equivalence was demonstrated at day 210 (lot A: 97.3% [95% CI: 92.4%, 99.4%] vs. lot B: 100.0% [97.0%, 100.0%]). Compared to 1A-HBV, lot B SPR was higher at day 180 (98.3% vs. 81.2%; difference: 17.1% [9.7%, 24.6%]) and non-inferior at day 210 (100% vs. 98.3%; difference: 1.7% [-0.6%, 4.1%]). 3A-HBV lot B showed the same SPR after 2 doses (98.3%) as 1A-HBV after 3 doses (98.3%). Adverse events (AEs) were comparable with both 3A-HBV lots (lot A: 68.7% vs. lot B: 54.2%), but higher than 1A-HBV (35.3%). Vaccination-related AEs included transient injection site pain (38.9%), myalgia (9.3%), and fatigue (7.5%). Eight serious AEs were reported (lot A: 3/134 [2.2%]; lot B: 1/134 [0.8%]; 1A-HBV: 4/133 [2.3%]). One serious AE, syncope, was noted as probably related to study vaccine, lot B. CONCLUSIONS: The two 3A-HBV lots had equivalent immunogenicity, but lot B elicited faster onset of seroprotection and higher anti-HBs titers than both lot A and 1A-HBV in an Asian population. This supports 3A-HBV lot B as an effective choice for HBV vaccination, with a favorable safety profile. ClinicalTrials.gov: NCT04531098.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Diaz-Mitoma F, Popovic V, Spaans JN, et al. Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: A phase 3 randomized clinical trial. Vaccine. 2021. PMID: 34116873. doi:10.1016/j.vaccine.2021.05.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。